Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology | Immunology
 Disease Category: Lymphoma
Location: United States, WV

Trial Information

ECOG 2408: A Three-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenolidomide/Rituxan in High Risk Follicular Lymphoma

Objective: To compare the CR rate of BR vs BVR as induction therapy. To compare the 1-year post-induction disease-free survival rates with rituximab plus lenolidomide to rituxan alone as continuation therapy.

West Virginia University - Clinical Trials Research Unit
1637 Health Sciences South
Morgantown, WV 26506
Phone: 304-293-4944

View Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.